Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Adult subjects (male or female ≥ 50 years); * Acute ischemic stroke patients (NIHSS ≤ 3 at the time of randomization) with type 2 diabetes mellitus within 24 hours of symptoms onset; * High-risk TIA patients (ABCD2 score ≥ 4 at the time of randomization) with type 2 diabetes mellitus within 24 hours of onset; * First stroke, or prior stroke without sequel (mRS score ≤ 1) and does not affect the NIHSS score; * Informed consent signed. Exclusion Criteria: * Diagnosis of hemorrhage brain disease on baseline head CT; * Iatrogenic and cardiogenic stroke; * Patients receiving thrombolysis or endovascular treatment; * Use of a GLP-1 analogue or any dipeptidyl peptidase-IV (DPP-IV) inhibitor within the 3 months prior to screening; * Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC); * Patients with pancreatitis or previous history of pancreatitis, inflammatory bowel disease and gastroparesis; * Pregnant, lactating women,or patients who are likely to have a pregnancy and plan to have one; * Allergic to liraglutide or excipients; * Congestive heart failure (NYHA class III-IV); * Severe liver and kidney dysfunction (AST/ALT is 3 times higher than the normal upper limit, serum creatinine is 3 times higher than the normal upper limit); * Patients with malignant tumors who are expected to have a survival period of less than three months; * Participated in other clinical trials of drugs within 3 m…